> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Rezolute Sizes Tumor Hyperinsulinism At $4-5 Billion, With Patients Needing Triple The Vials
- URL: https://www.bullished.co/rezolute-sizes-tumor-hyperinsulinism-at-4-5-billion-with-patients-needing-triple-the-vials-c8adbb53/
- Published: 2026-10-29T20:21:39.000Z
- Updated: 2026-10-29T20:21:39.000Z
- Description: The company's investor deck puts the U.S. opportunity for ersodetug at about 6,000 patients, driven by weight-based dosing.
- Author: Matteo Parrino
- Tags: SEC Filings, RZLT, Industry: Healthcare

[Rezolute](https://www.bullished.co/tag/rzlt/), a late-stage rare disease company developing therapies for dangerously low blood sugar linked to excess insulin, put the U.S. market for its antibody ersodetug at [about 6,000 addressable patients](https://www.sec.gov/Archives/edgar/data/0001509261/000110465926120205/tm2628517d1%5Fex99-1.htm?ref=bullished.co) in an investor presentation furnished in an [8-K](https://www.sec.gov/Archives/edgar/data/0001509261/000110465926120205/tm2628517d1%5F8k.htm?ref=bullished.co) on Thursday. Tumor patients, the deck says, need about three times as many vials as congenital patients under weight-based dosing.

## Tumor patients carry the market

The company pegs tumor hyperinsulinism at about 4,000 patients and a $4-5 billion total addressable market. Congenital hyperinsulinism, which affects children, is put at about 2,000 patients and $750 million to $1 billion.

Within the tumor group, the deck counts about 2,500 addressable malignant insulinoma patients and about 1,500 addressable patients with non-islet cell tumor hypoglycemia. Both figures are point-in-time prevalence as of October 2026 from the Veeva Compass database.

The company says the combined opportunity exceeds $5 billion, and cites a total of $5 billion or more globally.

## The vial math behind the numbers

The congenital maintenance dose is 10 mg/kg. A pediatric patient averaging about 24 kg uses 3 vials per infusion, or 39 vials a year on an every-four-week schedule.

The tumor maintenance dose is 9 mg/kg. An adult averaging about 80 kg uses 9 vials per infusion, or 117 vials a year.

Payer research, the company says, supports rare-disease, weight-based pricing for both indications. It expects prior authorization aligned to the label, with a step through diazoxide for insulinoma patients, and reimbursement through a J-code under buy-and-bill. Diazoxide is the first-line and only approved drug, and about 60% of patients do not respond to it.

## Where the programs stand

Rezolute has no approved products. In congenital disease, the main goal of the late-stage sunRIZE trial, cutting weekly hypoglycemia events, was not met. The company blames a placebo effect from functional unblinding. It says the FDA reviewed additional data at its request and encouraged a request for a pre-BLA meeting, the step before an approval application. The deck lists a BLA filing for 2027.

In tumor disease, the single-arm upLIFT study enrolls about 16 adults. An interim update reported that 7 of the first 8 met the main goal. The eighth entered hospice and died a week later of cancer progression, and the company counts that patient as a non-responder.

The deck lists $108 million in cash, with runway through the first quarter of 2028.

Topline upLIFT results are expected in mid-December 2026, and regulatory discussions on GI-surgery hypoglycemia are slated for the first half of 2027.

Learn

- [Item 7.01: Regulation FD disclosure →](https://www.bullished.co/learn/8-k-items-explained/#item-701-regulation-fd-disclosure)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Rezolute, Inc. (RZLT)](https://www.sec.gov/Archives/edgar/data/0001509261/000110465926120205/tm2628517d1%5F8k.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit tm2628517d1\_ex99-1.htm — Rezolute, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001509261/000110465926120205/tm2628517d1%5Fex99-1.htm?ref=bullished.co) — SEC EDGAR

### More on Rezolute

- [Jennison Associates Takes A 5.5% Passive Stake In Rezolute, Holding 5.3 Million Shares](https://www.bullished.co/jennison-associates-takes-a-5-5-passive-stake-in-rezolute-holding-5-3-million-shares-2ac28d6a/)
- [Rezolute's CEO Took Home $5,711,410 And Also Chairs The Board, Proxy Shows](https://www.bullished.co/rezolutes-ceo-took-home-5-711-410-and-also-chairs-the-board-proxy-shows-61925309/)
- [Rezolute Finishes Enrolling 16-Patient Tumor Hyperinsulinism Trial, Expects Topline Data Mid-December](https://www.bullished.co/rezolute-finishes-enrolling-16-patient-tumor-hyperinsulinism-trial-expects-topline-data-5dc3335f/)

[All Rezolute (RZLT) coverage →](https://www.bullished.co/tag/rzlt/)